亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

帕尼单抗 福尔菲里 医学 克拉斯 伊立替康 内科学 肿瘤科 结直肠癌 氟尿嘧啶 西妥昔单抗 危险系数 养生 化疗 癌症 置信区间
作者
Marc Peeters,Timothy Jay Price,Andrès M.R. Cervantes,Alberto Felice Sobrero,Michel Pierre Ducreux,Yevhen Hotko,Thierry André,Emily W. Chan,Florian Lordick,Cornelis J.A. Punt,Andrew H. Strickland,G. Wilson,Tudor–Eliade Ciuleanu,Laslo Roman,Eric Van Cutsem,Valentina Tzekova,Simon Collins,Kelly Smith Oliner,Alan Rong,Jennifer L. Gansert
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:28 (31): 4706-4713 被引量:1093
标识
DOI:10.1200/jco.2009.27.6055
摘要

PURPOSE: Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status. PATIENTS AND METHODS: Patients with mCRC, one prior chemotherapy regimen for mCRC, Eastern Cooperative Oncology Group performance status 0 to 2, and available tumor tissue for biomarker testing were randomly assigned 1:1 to panitumumab 6.0 mg/kg plus FOLFIRI versus FOLFIRI every 2 weeks. The coprimary end points of PFS and overall survival (OS) were independently tested and prospectively analyzed by KRAS status. RESULTS: From June 2006 to March 2008, 1,186 patients were randomly assigned 1:1 and received treatment. KRAS status was available for 91% of patients: 597 (55%) with wild-type (WT) KRAS tumors, and 486 (45%) with mutant (MT) KRAS tumors. In the WT KRAS subpopulation, when panitumumab was added to chemotherapy, a significant improvement in PFS was observed (hazard ratio [HR] = 0.73; 95% CI, 0.59 to 0.90; P = .004); median PFS was 5.9 months for panitumumab-FOLFIRI versus 3.9 months for FOLFIRI. A nonsignificant trend toward increased OS was observed; median OS was 14.5 months versus 12.5 months, respectively (HR = 0.85, 95% CI, 0.70 to 1.04; P = .12); response rate was improved to 35% versus 10% with the addition of panitumumab. In patients with MT KRAS, there was no difference in efficacy. Adverse event rates were generally comparable across arms with the exception of known toxicities associated with anti-EGFR therapy. CONCLUSION: Panitumumab plus FOLFIRI significantly improved PFS and is well-tolerated as second-line treatment in patients with WT KRAS mCRC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔的应助被lmn采纳,获得10
1秒前
酒酿是也完成签到 ,获得积分10
1秒前
满意的楷瑞完成签到,获得积分10
3秒前
顺利的水瑶完成签到 ,获得积分10
5秒前
8秒前
我是老大的应助被科研通管家采纳,获得10
8秒前
彭于晏的应助被科研通管家采纳,获得10
8秒前
8秒前
10秒前
慕青的应助被肖可声采纳,获得10
10秒前
田様的应助被重要白亦采纳,获得10
12秒前
科研通AI6.2的应助被Jeff采纳,获得20
13秒前
科研通AI6.3的应助被Jeff采纳,获得50
13秒前
烟花的应助被俏皮的灵采纳,获得10
14秒前
lmn发布了新的文献求助10
15秒前
20秒前
Maestro_S的应助被Kaikai采纳,获得10
21秒前
22秒前
肖可声完成签到,获得积分10
24秒前
mino完成签到 ,获得积分10
25秒前
26秒前
肖可声发布了新的文献求助10
28秒前
铃木完成签到,获得积分10
28秒前
重要白亦发布了新的文献求助10
30秒前
31秒前
31秒前
简啦啦完成签到 ,获得积分10
33秒前
迅速的天玉完成签到,获得积分20
33秒前
烟花的应助被风趣含双采纳,获得30
35秒前
自信的镜子完成签到,获得积分10
36秒前
万能图书馆的应助被seven采纳,获得10
37秒前
中華人民共和完成签到,获得积分10
39秒前
888的应助被肖可声采纳,获得30
40秒前
丸子完成签到 ,获得积分10
41秒前
43秒前
钉钉完成签到 ,获得积分10
45秒前
yangzai完成签到 ,获得积分0
50秒前
51秒前
Owen的应助被虚心的灵寒采纳,获得10
55秒前
科研通AI65的应助被虚心的灵寒采纳,获得10
55秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571